source
- Replimune secures FDA approval for Tudriqev, eyes $1.3 bn peak sales in advanced melanomaReplimune announced FDA approval of its therapy Tudriqev for patients with advanced melanoma who have progressed after PD-1 treatment. Analysts at BMO Capital Markets project the drug could genera…
- Revolution Medicines sees strong demand for pancreatic cancer drug daraxonrasib under compassionate useRevolution Medicines reports that more than 2,000 patients have received its pancreatic cancer candidate daraxonrasib through a compassionate use program. The company says the drug has been distri…